Enrolling by invitationNCT05635747

A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB

Studying Short bowel syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Boston Children's Hospital
Principal Investigator
Mark Puder, MD, PhD
Boston Children's Hospital
Intervention
Relizorb Enzyme Cartridge(device)
Enrollment
32 enrolled
Eligibility
2-18 years · All sexes
Timeline
2022 – 2027

Study locations (1)

Collaborators

Alcresta Therapeutics, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05635747 on ClinicalTrials.gov

Other trials for Short bowel syndrome

Additional recruiting or active studies for the same condition.

See all trials for Short bowel syndrome →

← Back to all trials